Brian Reed: Hey. Good to be back.
Eliza Ward: Yeah, likewise. You see what dropped Thursday?
Brian Reed: The Hovilpri approval — yeah, that landed in my feed and I had to sit with it for a minute. FDA greenlighted it October 9th. Asahi Kasei made the announcement the next day.
Eliza Ward: First novel HSV mechanism in roughly 30 years.
Brian Reed: Right — and that's the part I keep returning to. Thirty years is not a gap in the data, that's a gap in, I mean — someone made a decision that the existing drugs were sufficient. And then suddenly they weren't.
Eliza Ward: Wait, let me be precise about the indication though. This isn't for everyone with HSV. It's specifically immunocompromised adults — lesions that are refractory to acyclovir, valacyclovir, or famciclovir. All three.
Brian Reed: So the people who've already run out of options.
Eliza Ward: Exactly that population. And what I don't know yet — what no source I've seen actually specifies — is how many people that actually is in the U.S. annually. That number changes whether this is a significant public health moment or a very narrow regulatory win.
Brian Reed: But the narrow population is kind of the point, mechanically — because the reason those patients ran out of options is actually the interesting part. The old drugs, acyclovir, valacyclovir, famciclovir — they all need the virus to hand them a key. Like, the virus has its own enzyme, thymidine kinase, and it activates the drug. Resistant HSV just... changes the key. Mutates or loses that enzyme. And then the drug can't get in.
Eliza Ward: Which means pritelivir picks a different lock entirely.
Brian Reed: Right — a lock the virus can't easily swap out. The helicase-primase complex, which is involved in actually copying HSV's DNA. And that process doesn't run through thymidine kinase at all. So resistant strains don't have a workaround.
Eliza Ward: That's — yeah. That's the actual news. Not 'new drug.' Different target. Genuinely independent pathway.
Brian Reed: And Aicuris had this data in front of regulators — they presented the Phase 3 results at ASCMID in April 2026. So the FDA had roughly six months to look at it before the October 9th approval.
Eliza Ward: Priority Review designation, too. Which — that's not automatic. That's the agency saying this addresses an unmet need with no adequate alternative.
Brian Reed: So the 30-year gap isn't, I mean — it's not that the science was impossible. Helicase-primase was a known target. The gap is that nobody moved on it because acyclovir worked fine for most people.
Eliza Ward: Right. And actually — wait, this is the thing the headline buries — the PRIOH-1 trial, NCT03073967, got to 63% complete lesion healing by day 28 versus 34% on comparator. That's a real gap. But those patients had already failed the drugs we just described.
Brian Reed: So the question isn't whether the lock-pick works. It's who's standing at that door.
Eliza Ward: That door, though — I want to push on who's actually behind it, because the framing that's already out there is wrong. I'm seeing 'new era for HSV treatment' and that's — no. The label doesn't say that.
Brian Reed: What does the label actually restrict?
Eliza Ward: Hovilpri's approval explicitly does not extend to otherwise healthy adults. Not cold sores. Not routine recurrent genital herpes. It's specifically immunocompromised adults with mucocutaneous lesions refractory to standard antivirals. That's the actual label.
Brian Reed: So picture someone — I mean, let me make this concrete. Someone living with lupus, on immunosuppressants, who's been on acyclovir for two years and their lesions on, say, the lip or genitals just won't clear. Clinical guideline threshold is seven to ten days without resolution — that's when resistance gets suspected. That person is the indicated patient. Not your friend who gets a cold sore in January.
Eliza Ward: Right. And here's where the take falls apart — the 'new era' framing collapses the moment you ask how many people that actually is. No source quantifies the refractory immunocompromised HSV population in the U.S. I've looked. The number isn't there.
Brian Reed: Which means we genuinely don't know if this is thousands of patients a year or tens of thousands.
Eliza Ward: And that gap — that missing number — is what separates a public health moment from a very targeted regulatory win for a narrow population. Both could be true of Hovilpri. We just can't say which yet.
Brian Reed: The part that complicates this further — and we'll get into it — is what the PRIOH-1 data actually proves versus what we're inferring about real-world use, because the trial design has a caveat that matters a lot when you're reading that 63% number.
Eliza Ward: Yeah. The 'new era' headline doesn't survive contact with that either.
Brian Reed: That caveat is the part that bothers me. PRIOH-1 was open-label. Patient knew they got pritelivir. The investigator knew. Nobody was blinded. And then you get 63% versus 34% and you have to ask — how much of that gap is the drug and how much is, I mean, the psychological weight of being the person who finally got something new after failing three drugs?
Eliza Ward: Okay, but — wait. Complete lesion healing by day 28 is an objective endpoint. You can see whether a lesion healed.
Brian Reed: Sure. Though the investigator scoring the healing is also unblinded.
Eliza Ward: Right — no, that's fair. That's actually the sharper version of the concern. It's not just patient expectation. The person calling 'complete healing' knows which arm they're looking at. That — yeah, that puts a real ceiling on confidence in the exact magnitude of the gap.
Brian Reed: And it probably can't be fixed retroactively with a blinded trial — refractory patients in this population, you can't ethically withhold the one available alternative for long enough. So what we have is what we have.
Eliza Ward: Which is: the direction of the result is credible, the size of the gap is less certain. The adverse event picture is actually pretty clean — headache was the most commonly reported reaction. That's manageable. That's not a signal that kills the drug in real-world use.
Brian Reed: The access question though. No listed price, no confirmed patient assistance program from Asahi Kasei Therapeutics. And this is a population — immunocompromised adults, often on multiple expensive medications already — where that gap is not hypothetical. Imagine an infectious disease physician right now trying to get this approved through a payer for a transplant patient whose famciclovir course failed. There's no price to anchor the prior auth to.
Eliza Ward: And the Aicuris, Asahi Kasei relationship — the exact structure of that licensing arrangement isn't confirmed. Who controls pricing decisions, who's responsible for access programs — we don't actually know how that's divided.
Brian Reed: So the concrete thing to watch is: does Asahi Kasei publish a list price and patient access terms before Hovilpri actually reaches a pharmacy? Because approval is the easy part. That transplant patient's physician can't prescribe goodwill.
Eliza Ward: And that's — I mean, that's actually where I land. The October 9th approval is a real thing. The helicase-primase mechanism is genuinely novel. The PRIOH-1 result is directionally credible. What I can't tell you is whether pritelivir stays inside that narrow refractory-immunocompromised label forever or whether Asahi Kasei eventually pushes toward immunocompetent adults — the much larger HSV population. That's not addressed anywhere in what's available. That's a future regulatory question, a future commercial calculation, and we don't have it.
Brian Reed: And that's — yeah, that's the question I can't shake. Does approving it only for the sickest patients actually close the 30-year mechanistic gap, or does it just prove the gap stays open unless the commercial logic forces it shut? Because the trade press picked this up October 13th — four days after approval — and the practicing clinicians reading it that Monday morning, they can't expand the label themselves.
Eliza Ward: No verdict on that yet.
Brian Reed: Not from what's been published. The thing that would actually settle it — I mean, not settle everything, but settle the next piece — is whether Asahi Kasei files for a broader indication. That hasn't happened. That might not happen. And until it does, the honest answer is: pritelivir works, for a carefully selected group, through a mechanism that genuinely didn't exist in an approved drug before. Everything past that is inference.
Eliza Ward: That's where we are. Genuinely.
